Veeva Systems Shares Surge 19% as AI Role Expands in Life Sciences Sector

Shares of Veeva Systems, a life sciences software company, rose 19% in a single session, driven by strong second-quarter results reflecting rising demand from pharmaceutical and medical research companies.

Veeva's platform enables pharmaceutical companies to manage R&D, regulatory registration, and physician relations through a unified software environment, and the company has been adding AI capabilities to accelerate drug development cycles.

Analysts noted that the life sciences software market is undergoing a structural shift, as major pharmaceutical companies deploy artificial intelligence to shorten the time between scientific discovery and bringing drugs to market.

These figures indicate that the life sciences software sector is undergoing an upward revaluation as AI proves capable of reducing medical research costs and accelerating results.

What Do These Terms Mean?

Life Sciences: A scientific field that encompasses biology, medicine, pharmaceuticals, and biotechnology. Companies like Veeva serve this sector with specialized software tools.

Drug Development Cycle: The stages from lab discovery to reaching pharmacies, typically taking between 10 and 15 years and costing billions of dollars.

Regulatory Registration: Obtaining approvals from regulatory bodies such as the US FDA before selling a drug, requiring massive documentation and clinical trial data.